The pharmacokinetics of MYRBETRIQIn patients with moderate hepatic impairment (Child-Pugh Class B), the daily dose of MYRBETRIQNo dose adjustment is necessary based on gender. Contact the applicable plan Mechanism Of Action Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR.
Drugs 2002 Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment.

Revised: July 2017.Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.In three, 12-week, double-blind, placebo-controlled, safety and efficacy studies in patients with The most frequent adverse events (0.2%) leading to discontinuation in Studies 1, 2 and 3 for the 25 mg or 50 mg dose were nausea, headache, Table 1 lists adverse reactions, derived from all adverse events, that were reported in Studies 1, 2 and 3 at an incidence greater than placebo and in 1% or more of patients treated with MYRBETRIQOther adverse reactions reported by less than 1% of patients treated with MYRBETRIQTable 2 lists the rates of the most commonly reported adverse reactions, derived from all adverse events in patients treated with MYRBETRIQIn a separate clinical study in Japan, a single case was reported as Because these spontaneously reported events are from the worldwide postmarketing experience, from a population of uncertain size, the frequency of events and the role of mirabegron in their causation cannot be reliably determined.The following events have been reported in association with mirabegron use in worldwide postmarketing experience:There have been postmarketing reports of confusion, hallucinations, insomnia and anxiety in patients taking mirabegron. Myrbetriq is a beta-3 adrenergic agonist and Ditropan is an antispasmodic and anticholinergic. When these muscle contractions happen too often or cannot be controlled, you can get symptoms of overactive bladder, which are urinary frequency, You are encouraged to report negative side effects of prescription drugs to the FDA. Treatment for overdosage should be symptomatic and supportive. provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. vibegron-4000077 Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).Mirabegron is transported and metabolized through multiple pathways. Myrbetriq and Ditropan belong to different drug classes. 8.7 Mechanism of Action Help New Window Mirabegron is a potent and selective agonist for beta-3 adrenergic receptors. Studies of mirabegron using human liver microsomes and Mirabegron inhibited P-gp-mediated drug transport at high concentrations. Visit the Copyright © 2020 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvbXlyYmV0cmlxLW1pcmFiZWdyb24tOTk5NzU3 Elevated BP occurring predominantly in patients with preexisting hypertension (7.5-11.5%)GI disorders (eg, dyspepsia, gastritis, abdominal distension)Renal and urinary disorders (eg, nephrolithiasis, bladder pain)Reproductive system disorders (eg, vulvovaginal pruritis, vaginal infection)Skin and subcutaneous tissue disorders (eg, urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubinAngioedema of the face, lips, tongue, and larynx, with or without respiratory symptomsMay increase blood pressure; monitor blood pressure periodically, especially in hypertensive patients; not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg)Urinary retention may occur with bladder outlet obstruction or with concomitant antimuscarinic therapy; administer with caution in these patientsAngioedema of the face, lips, tongue, and/or larynx reported; may occur after the first dose or following multiple doses; promptly discontinue and initiate appropriate therapy to ensure a patent airwayThere are no studies with the use in pregnant women to inform drug-associated risk for birth defects or miscarriageThere is no information on the presence of mirabegron in human milk, the effects on the breastfed child, or the effects on milk productionMirabegron-related material was present in rat milk and in the stomach of nursing pups following administrations of a single 10 mg/kg oral dose of 14C-labeled mirabegron to lactating ratsA: Generally acceptable.